SCHEMBL3963241

SCHEMBL3963241

CCCCCCCCCN(Cc1ccc(F)cc1F)C(=O)COc1ccc(C[C@](CC)(OCC)C(=O)O)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 5/20 0.46
PPARG P37231 4/20 0.46
SOAT1 P35610 1/20 0.43
HTR2A P28223 4/20 0.42
PPARD Q03181 2/20 0.40
USP2 O75604 1/20 0.39
HSD17B10 Q99714 1/20 0.39
LTB4R2 Q9NPC1 1/20 0.39
TP53 P04637 2/20 0.37
MAPT P10636 2/20 0.37
GAA P10253 1/20 0.37
THRB P10828 1/20 0.37
TRPM8 Q7Z2W7 1/20 0.36
PTPN11 Q06124 1/20 0.36
PTPRO Q16827 1/20 0.36
PSEN1 P49768 1/20 0.36
PSEN2 P49810 1/20 0.36
APH1B Q8WW43 1/20 0.36
NCSTN Q92542 1/20 0.36
APH1A Q96BI3 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3964923 1.00 PPARA (0.46) PPARAPPARGSOAT1HTR2APPARD
SCHEMBL3965294 1.00 PPARA (0.46) PPARAPPARGSOAT1HTR2APPARD
SCHEMBL3960463 0.88 PPARD (0.44) PPARAPPARGHTR2APPARDUSP2
SCHEMBL3956940 0.87 MAPT (0.43) HTR2ATP53MAPTGAATHRB
SCHEMBL3960798 0.84 TRPM8 (0.49) USP2HSD17B10LTB4R2TRPM8
SCHEMBL3959943 0.84 HTR2A (0.42) PPARAPPARGHTR2APPARD
SCHEMBL3961314 0.82 BCHE (0.47) USP2HSD17B10
SCHEMBL3967728 0.81 PPARG (0.45) PPARAPPARGPPARDTRPM8
SCHEMBL4073462 0.80 PPARA (0.47) PPARAPPARGHTR2APPARD
SCHEMBL3965062 0.80 PPARA (0.47) PPARAPPARGHTR2APPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7488844-B2 Therapeutic agents ASTRAZENECA AB (SE) 2009-02-10 US disclosed
US-20050282822-A1 Therapeutic agents ASTRAZENECA AB (SE) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282822-A1 Therapeutic agents GPR119, LIPC, PNLIP PPARA 346/4885PPARG 228/4885SOAT1 115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.